Analyst consensus rating
Lexeo Therapeutics Analyst Rating: Strong Buy
LXEO is rated Strong Buy by 10 analysts with a $20.30 target. As of 2026-08-29.
Direct answer
Lexeo Therapeutics's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.30.
Forecast evidence checked August 29, 2026.
Get free Lexeo Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.86
- Average price target
- $20.30
- High price target
- $30.00
- Low price target
- $9.00
- Low target gap
- +85.2%
- Target upside
- +317.7%
- High target gap
- +517.3%
- Target range width
- 432.1%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lexeo Therapeutics?
Lexeo Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $20.30.
How far are Lexeo Therapeutics's low and high targets from the recorded price?
The low target implies +85.2%, while the high target implies +517.3%.
How many analysts are included in Lexeo Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Lexeo Therapeutics's target upside or downside calculated?
The average target of $20.30 is divided by the recorded price of $4.86, then one is subtracted to produce +317.7%. This does not guarantee a future return.
When was Lexeo Therapeutics's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.